FDA approves generic cetrorelix acetate injection
The FDA has approved cetrorelix acetate for injection, a generic version of Cetrotide, for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian stimulation.
The US Food and Drug Administration has approved cetrorelix acetate for injection (Akorn Operating Company, a Calyptus partner), a generic version of Cetrotide (Merck Global), for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian stimulation.1
Controlled ovarian stimulation is a fertility process by which oral and/or injectable medications are administered to induce superovulation in the ovulatory patient, and ovulation in the anovulatory patient.
“As an industry leader in specialty injectable offerings, Akorn is uniquely positioned to launch the product in the US. We are excited that this approval will broaden accessibility to medication for patients undergoing controlled ovarian stimulation,” said Calyptus co-founders Sujeet Singh, Dr. Puiho Yuen, and Shubhayu Sinharoy.
They added, “This is an important milestone for Calyptus and further validates our impressive track record of selecting and developing complex sterile dosage forms with an eye toward execution, along with our ability to piece together complex supply chains."
Reference:
Calyptus pharmaceuticals announces FDA approval of cetrorelix acetate for injection, 0. 25 mg/vial. PR Newswire. August 19, 2022. Accessed August 19, 2022. https://www.prnewswire.com/news-releases/calyptus-pharmaceuticals-announces-fda-approval-of-cetrorelix-acetate-for-injection-0-25-mgvial-301608717.htmlThe US Food and Drug Administration has approved cetrorelix acetate for injection (Akorn Operating Company, a Calyptus partner), a generic version of Cetrotide (Merck Global), for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian stimulation.1
Controlled ovarian stimulation is a fertility process by which oral and/or injectable medications are administered to induce superovulation in the ovulatory patient, and ovulation in the anovulatory patient.
“As an industry leader in specialty injectable offerings, Akorn is uniquely positioned to launch the product in the US. We are excited that this approval will broaden accessibility to medication for patients undergoing controlled ovarian stimulation,” said Calyptus co-founders Sujeet Singh, Dr. Puiho Yuen, and Shubhayu Sinharoy.
They added, “This is an important milestone for Calyptus and further validates our impressive track record of selecting and developing complex sterile dosage forms with an eye toward execution, along with our ability to piece together complex supply chains."
Reference:
Calyptus pharmaceuticals announces FDA approval of cetrorelix acetate for injection, 0. 25 mg/vial. PR Newswire. August 19, 2022. Accessed August 19, 2022. https://www.prnewswire.com/news-releases/calyptus-pharmaceuticals-announces-fda-approval-of-cetrorelix-acetate-for-injection-0-25-mgvial-301608717.html
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
